Moderna (MRNA) is back in focus after a unanimous FDA advisory panel vote that its investigational mRNA flu vaccine, mFlusiva, has a favorable benefit risk profile in adults 50 and older.

Moderna’s recent regulatory win has arrived after a sharp rebound in the stock, with a 1-year total shareholder return of 146.95% and a year to date share price return of 107.26%, while the 3 and 5 year total shareholder returns remain significantly lower. This suggests renewed momentum following a period of weaker long term performance.

If Moderna’s mRNA flu progress has caught your attention, it could be a useful time to look across other healthcare-focused mRNA and AI opportunities using the 40 healthcare AI stocks.

Moderna’s share price has risen significantly compared with a year ago, while analysts’ average price target currently sits below the market price and the company is still reporting losses. Is there a fresh opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 38.7% Overvalued

At a last close of $63.96 against a narrative fair value of $46.10, the most followed Moderna narrative suggests the market price sits well above its modeled worth, with that view anchored in detailed assumptions about future vaccine demand, margins, and capital needs.

The analysts have a consensus price target of $46.1 for Moderna based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $135.0, and the most bearish reporting a price target of just $21.0.

Read the complete narrative. Read the complete narrative.

Want to understand why this narrative implies a richer future earnings multiple despite ongoing losses today? The key assumptions tie projected revenue growth and margins to a concentrated pipeline and later stage programs, with a required return that still supports a higher equity value. Curious which specific growth and profitability paths need to play out for that to hold.

Result: Fair Value of $46.10 (OVERVALUED)

However, Moderna’s story can still change quickly if COVID vaccine revenues weaken further or if litigation related payments and outcomes are less favorable than modeled.

Next Steps

Given the mixed sentiment around Moderna’s valuation and future earnings path, it could be worth acting now to review the underlying data and form your own judgement on the 1 key reward

Looking for more Moderna investment ideas?

If Moderna has sharpened your focus, do not stop here. Broaden your watchlist with a few targeted stock ideas that could sharpen your overall portfolio decisions.

• Spot potential mispricings early by scanning a focused set of companies using the 45 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks that feature reliable payouts through the 8 dividend fortresses.
• Sleep easier at night by filtering for companies with steadier risk profiles using the 65 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.